Abstract
In the ABSORB trial, the feasibility of using a fully bioabsorbable everolimus-eluting stent (BVS; Abbott Vascular, Santa Clara, CA) in patients with ischemia and a single de novo coronary lesion was investigated. Some important concerns about the efficacy of this device were raised by this study. The in-stent late loss with the BVS (0.44 mm) was comparable to that seen with some drug-eluting stents currently on the market, and the late lumen loss was primarily due to reduction in stent area. Technical improvements aimed at definitively preventing late vessel recoil and negative remodeling, as well as clarification of the behavior of these devices with longer follow-up, are needed before fully bioabsorbable drug-eluting stents can be considered a therapeutic option for patients with coronary artery disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stettler C et al. (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370: 937–948
Jensen LO et al. (2007) Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50: 463–470
Erbel R et al. for the PROGRESS-AMS investigators (2007) Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369: 1869–1875
Ormiston JA et al. (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371: 899–907
Di Mario C and Ferrante G (2008) Biodegradable drug-eluting stents: promises and pitfalls. Lancet 371: 873–874
Moreno R et al. (2007) Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J 28: 1583–1591
Grube E et al. (2004) Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109: 2168–2171
Kiemeneij F et al. (2001) Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol 37: 1598–1603
Serruys PW on behalf of the SPIRIT II Investigators (2008) SPIRIT II study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. Presented at the Society for Cardiovascular Angiography and Interventions and the American College of Cardiology i2 Summit (SCAI-ACCi2): 2008 March 29 to April 1, Chicago, IL
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Macaya, C., Moreno, R. Bioabsorbable drug-eluting stents: the future of coronary angioplasty?. Nat Rev Cardiol 5, 598–599 (2008). https://doi.org/10.1038/ncpcardio1306
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1306
